middle.news
Neurotech Doubles Loss Amid Clinical Breakthroughs for NTI164
4:22am on Saturday 30th of August, 2025 AEST
•
Biotechnology
Read Story
Neurotech Doubles Loss Amid Clinical Breakthroughs for NTI164
4:22am on Saturday 30th of August, 2025 AEST
Key Points
23% decline in revenue to $2.58 million
Net loss doubled to $10.6 million
Strong clinical trial results in Autism Spectrum Disorder and Rett Syndrome
Orphan drug designations granted by FDA and European Commission
Read Story
middle.
Tap to Read
Tap the card to read the full analysis
about
Neurotech International (ASX:NTI)
OPEN ARTICLE